A Phase 1/2 interventional study of Surzebiclimab and Tislelizumab in Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion and NSCLC for Phase 2 Dose Expansion, sponsored by BeiGene. Completed at 40 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.
Sponsored by BeiGene · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck — 8 open to participants now, 13 under way, none of them phase 3. tislelizumab · Squamous Cell Carcinoma of Head and Neck.
Among the 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck, this one is the 3rd largest by enrollment, is the only one that started in 2018, is one of 3 in phase 1/2, and was the 1st registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →8 of the 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck are open now, in 2 countries. Recruiting first, the newest first:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Sites in China
Ages 18+
Beijing Tongren Hospital · Sites in China
Ages 18+
Weijia Fang, MD · Sites in China
Ages 18–75
University of Chicago · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15
First in 2018; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 147 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 41 across the 16 interventional studies. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 4 studies filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
3 of the studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06725498Beijing Tongren HospitalIntra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC | 2026-11-30 |
| NCT06978829Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityCetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC | 2027-03-31 |
| NCT07010120West China HospitalA Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing tislelizumab in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of surzebiclimab (BGB-A425) and/or alcestobart (LBL-007) with tislelizumab.
Blocking antibodies targeting programmed cell death protein-1 (PD-1) have achieved remarkable results in the treatment of many types of tumors. However, based upon the rate of primary and secondary resistance to PD-1 blockade, it was apparent that additional immuno-regulatory mechanism(s) underlie tumor immune escape. Indeed, research shows that the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) pathway cooperates with PD-1 to maximize the suppression of effector tumor infiltrating lymphocytes (TILs) as well as promote resistance to anti-PD-1 therapy. Therefore, TIM-3 represents an ideal target with the potential to significantly improve and/or extend the therapeutic benefit of anti-PD-1 therapy to a greater number of participants.
TIM-3, Lymphocyte activation gene-3 (LAG-3), and PD-1 function as immune checkpoint receptors in the overlapping regulation of immune tolerance and have been shown to be co-overexpressed on the TILs from the participant samples of various solid tumors. Furthermore, emerging clinical data and preclinical data demonstrate co-expression of TIM-3, LAG-3, PD-1 often yield T cells exhausted immunophenotype (i.e., cytokine expression, proliferation etc.). Cancer cells take advantage of PD-1, TIM-3, and LAG-3 in inhibiting immune cells' function, and escape the immune surveillance. Based upon the overlapping expression profiles and immuno-regulatory functions, TIM-3 and LAG-3 mediated adaptive resistance, there was strong scientific rationale that simultaneous targeting of these checkpoint blockers, could potentially increase therapeutic benefit and might help to overcome the resistance arising due to anti-PD-(L)-1 therapy. Hence, this study evaluated the safety and preliminary efficacy of surzebiclimab (anti TIM-3), alcestobart (Anti-LAG-3) in combination with tislelizumab (anti PD-1) in patients with advanced solid tumors.
This was an open-label, multicenter, nonrandomized Phase 1 and Phase 2 clinical trial. Phase 1 determined the recommended phase 2 dose (RP2D) for the combination of surzebiclimab and tislelizumab. Phase 2 safety lead-in determined the RP2D for the combination of surzebiclimab, tislelizumab and/or alcestobart. Phase 2 dose expansion continued to evaluate the safety but also focus on the efficacy of the doublet or triplet treatment combination in select tumor types.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria might apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received surzebiclimab 2 mg intravenous (IV) infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 2 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab
Participants received surzebiclimab 6 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 6 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab
Participants received surzebiclimab 20 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 20 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab
Participants received surzebiclimab 60 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 60 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab
Participants received surzebiclimab 200 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 200 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab
Participants received surzebiclimab 400 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 400 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter, until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab
Participants received surzebiclimab 800 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 800 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab
Participants received surzebiclimab 1600 mg IV infusion on day 1 of each cycle. In the first cycle, tislelizumab 200 mg was administered intravenously on Day 8. If tolerated, participants received surzebiclimab 400 mg along with tislelizumab sequentially on Day 29 and every 21 days (i.e., once every 21 days) thereafter until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Cycle 1 consisted of 28 days, and each cycle from Cycle 2 onwards consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab
Participants received one dose of surzebiclimab 60 mg IV infusion on Day 1 of Cycle 1 and discontinued the study treatment. Cycle 1 consisted of 28 days.
Drug: Surzebiclimab
Participants received one dose of surzebiclimab 1600 mg IV infusion on Day 1 of Cycle 1 and discontinued the study treatment. Cycle 1 consisted of 28 days.
Drug: Surzebiclimab
Participants received alcestobart 300 mg IV infusion on day 1 of each cycle along with tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.
Drug: Tislelizumab · Drug: Alcestobart
Participants received alcestobart 600 mg IV infusion on day 1 of each cycle along with tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.
Drug: Tislelizumab · Drug: Alcestobart
Participants received alcestobart 1200 mg IV infusion on day 1 of each cycle along with tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.
Drug: Tislelizumab · Drug: Alcestobart
Participants received alcestobart 300 mg IV infusion on day 1 of each cycle along with surzebiclimab 600 mg IV and tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.
Drug: Tislelizumab · Drug: Alcestobart
Participants received alcestobart 600 mg IV infusion on day 1 of each cycle along with surzebiclimab 600 mg IV and tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab · Drug: Alcestobart
Participants received alcestobart 900 mg IV infusion on day 1 of each cycle along with surzebiclimab 600 mg IV and tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab · Drug: Alcestobart
Participants with head and neck squamous cell carcinoma (HNSCC) received surzebiclimab 600 mg IV infusion on day 1 of each cycle along with tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab
Participants with non-small cell lung cancer (NSCLC) received surzebiclimab 600 mg IV infusion on day 1 of each cycle along with tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab
Participants with HNSCC received surzebiclimab 600 mg IV infusion on day 1 of each cycle along with alcestobart 600 mg IV and tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab · Drug: Alcestobart
Participants with NSCLC received surzebiclimab 600 mg IV infusion on day 1 of each cycle along with alcestobart 600 mg IV and tislelizumab 200 mg IV once every 21 days until they were no longer considered to receive clinical benefit, unacceptable toxicity, or withdrawal of informed consent. Each cycle consisted of 21 days.
Drug: Surzebiclimab · Drug: Tislelizumab · Drug: Alcestobart
Humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody against TIM-3
Also known as: BGB-A425
Humanized, IgG4-variant monoclonal antibody against PD-1
Also known as: BGB-A317
Human anti LAG-3 antibody
Also known as: LBL-007
Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An Adverse Event (AE) was defined as any unfavorable and unintended sign, symptom, or disease associated with the use of study drugs, whether considered related to study drugs or not. TEAE was an AE that has an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of the first new systemic anticancer therapy, whichever occurred first. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly or was considered a medically significant. Severity of AEs was assessed according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) v.5.0, which consists of: Grade 1 Mild; Grade 2 Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death due to AE.
Time frame: Up to 30 days after last dose of study drug (maximum treatment duration: up to 32.7 months)
Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Surzebiclimab in Combination With Tislelizumab
The MAD was defined as the highest dose administered, where all dose levels were tolerated during dose escalation. The MTD was not reached in Phase 1, therefore the MAD was reported.
Time frame: Up to 28 days
Phase 1: Recommended Phase 2 Dose (RP2D) of Surzebiclimab in Combination With Tislelizumab
The RP2D or recommended dose for expansion of the combination treatment was determined based upon the MTD or MAD, and also considered the long-term tolerability, PK, efficacy, and any other relevant data as available.
Time frame: Up to 28 days
Phase 2 (Safety Lead-In): Number of Participants With TEAEs and SAEs
An AE was defined as any unfavorable and unintended sign, symptom, or disease associated with the use of study drugs, whether considered related to study drugs or not. TEAE was an AE that has an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of the first new systemic anticancer therapy, whichever occurred first. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly or was considered a medically significant. Severity of AEs was assessed according to NCI-CTCAE v.5.0, which consists of: Grade 1 Mild; Grade 2 Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death due to AE.
Time frame: Up to 30 days after last dose of study drug (maximum duration of treatment: up to 19.6 months in Cohort A and up to 21.5 months in Cohort B)
Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Tislelizumab
The MAD was defined as the highest dose administered, where all dose levels were tolerated during dose escalation. The MTD was not reached in Phase 2, therefore the MAD was reported.
Time frame: Up to 21 days
Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Surzebiclimab and Tislelizumab
The MAD was defined as the highest dose administered, where all dose levels were tolerated during dose escalation. The MTD was not reached in Phase 2, therefore the MAD was reported.
Time frame: Up to 21 days
Phase 2 (Safety Lead-In): RP2D of Alcestobart in Combination With Surzebiclimab and Tislelizumab
The RP2D or recommended dose for expansion of the combination treatment was determined based upon the MTD or MAD, and also considered the long-term tolerability, PK, efficacy, and any other relevant data as available.
Time frame: Up to 21 days
Phase 2 (Dose Expansion): Overall Response Rate (ORR)
ORR was defined as the percentage of participants who had complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to11.3 months, Cohort 5: up to 15.9 months
Phase 1: Overall Response Rate (ORR)
ORR was defined as the percentage of participants who had CR or PR. Per RECIST v.1.1, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Maximum time on study: up to 57.5 months
Phase 2 (Safety Lead- In): Overall Response Rate (ORR)
ORR was defined as the percentage of participants who had CR or PR. Per RECIST v.1.1, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Maximum time on study: Cohort A: up to 22.1 months; Cohort B: up to 21.5 months
Phase 1: Disease Control Rate (DCR)
DCR was defined as the percentage of participants with a best overall response (BOR) of CR, PR, or stable disease (SD), per RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.
Time frame: Maximum time on study: up to 57.5 months
Phase 2 (Safety Lead-In): Disease Control Rate (DCR)
DCR was defined as the percentage of participants with a BOR of CR, PR, or SD, per RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Maximum time on study: Cohort A: up to 22.1 months; Cohort B: up to 21.5 months
Phase 2 (Dose Expansion): Disease Control Rate (DCR)
DCR was defined as the percentage of participants with a BOR of CR, PR, or SD, per RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months
Phase 2 (Dose Expansion): Duration of Response (DOR)
DOR was defined as the time from the first determination of an overall response per RECIST v1.1 until the first documentation of progression or death, whichever came first. DOR was estimated using the Kaplan-Meier method. Per RECIST v.1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
Time frame: From the first determination of an overall response until PD or death, whichever came first (Maximum time on study [Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months])
Phase 2 (Dose Expansion): Progression Free Survival (PFS)
Progression free survival was defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of disease progression assessed by investigator or death, whichever occurred first as determined from investigator derived tumor assessments per RECIST 1.1. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
Time frame: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months
Phase 1: Maximum Observed Plasma Concentration (Cmax) of Surzebiclimab
The maximum observed plasma concentration of surzebiclimab was measured in Cycle 1 and Cycle 5.
Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI; within 30 minutes), 6 hours, 1, 3, 7, 14, 21, and 28 (cycle 1 only) days after EOI. Cycle 1 was 28 days and Cycle 5 was 21 days.
Phase 2 (Dose Expansion): Cmax of Surzebiclimab
Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Phase 1: Minimum Observed Plasma Concentration (Cmin) of Surzebiclimab
Cmin of surzebiclimab was determined.
Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 (cycle 1 only) days after EOI (Cycle 1 was 28 days; Cycle 2 and thereafter were 21 days)
Phase 2 (Dose Expansion): Cmin of Surzebiclimab
Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI
Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Surzebiclimab
Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 (cycle 1 only) days after EOI (Cycle 1 was28 days; Cycle 2 and thereafter were 21 days)
Phase 2 (Dose Expansion): Tmax of Surzebiclimab
Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Phase 1: Half-Life (t1/2) of Surzebiclimab
Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 days after EOI (Cycle 1 was 28 days)
Phase 2 (Dose Expansion): T1/2 of Surzebiclimab
Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Phase 1: Area Under Curve From 0 to 21 Days (AUC0-21d) of Surzebiclimab
Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (Cycle 1 was 28 days; Cycle 2 and thereafter were 21 days)
Phase 2 (Dose Expansion): AUC0-21d of Surzebiclimab
Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle duration= 21 days)
Phase 1: Clearance (CL/F) of Surzebiclimab
Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 days after EOI (Cycle 1 was 28 days)
Phase 2 (Dose Expansion): CL/F of Surzebiclimab
Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI
Phase 1: Volume of Distribution (Vz/F) of Surzebiclimab
Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, 21, and 28 days after EOI (Cycle 1 was 28 days)
Phase 2 (Dose Expansion): Vz/F of Surzebiclimab
Vz/F of surzebiclimab was determined.
Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI
Phase 2 (Safety Lead-In): Cmax of Alcestobart
Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Phase 2 (Safety Lead-In): Cmin of Alcestobart
Cmin of alcestobart was determined.
Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Phase 2 (Safety Lead-In): Tmax of Alcestobart
Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Phase 2 (Safety Lead-In): t1/2 of Alcestobart
Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Phase 2 (Safety Lead-In): AUC0-21d of Alcestobart
Time frame: Cycle 1 Day 1 and Cycle 5 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI (each cycle was 21 days)
Phase 2 (Safety Lead-In): CL/F of Alcestobart
Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI
Phase 2 (Safety Lead-In): Vz/F of Alcestobart
Time frame: Cycle 1 Day 1 at pre-dose, end of infusion (EOI), 6 hours, 1, 3, 7, 14, and 21 days after EOI
Phase 1: Serum Concentrations of Tislelizumab
Serum concentrations of tislelizumab were measured using an enzyme-linked immunosorbent assay (ELISA).
Time frame: Pre-dose and EOI (within 30 minutes) on Cycle 1 Day 8 and Cycle 5 Day 1, and pre-dose on Day 1 of Cycles 2, 3, 6, 9, 13, 17, and 25 (Cycle 1 was 28 days, Cycle 2 and thereafter were 21 days)
Phase 2 (Dose Expansion): Serum Concentrations of Tislelizumab
Serum concentrations of tislelizumab were measured using an enzyme-linked immunosorbent assay (ELISA).
Time frame: Pre-dose on Day 1 of Cycles 1, 2, 5, 6, 9, 13, 17, 25 and at EOI (within 30 minutes) on Day 1 of Cycles 1 and 5 (each cycle was 21 days)
Phase 1: Number of Participants With Anti-Drug Antibodies (ADA) to Surzebiclimab
Immunogenic responses to surzebiclimab included: treatment emergent, treatment-induced and treatment boosted anti-drug antibodies (ADA) and neutralizing antibody (NAb) positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the Baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive Nab at any time including baseline and/or after drug administration.
Time frame: Maximum time on study: up to 57.5 months
Phase 2 (Safety Lead-In) Cohort B: Number of Participants With Anti-Drug Antibodies to Surzebiclimab
Immunogenic responses to surzebiclimab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
Time frame: Maximum time on study in Cohort B: up to 21.5 months
Phase 2 (Dose Expansion): Number of Participants With Anti-Drug Antibodies to Surzebiclimab
Immunogenic responses to surzebiclimab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
Time frame: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months
Phase 2 (Safety Lead-In): Number of Participants With Anti-Drug Antibodies to Alcestobart
Immunogenic responses to alcestobart included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
Time frame: Maximum time on study: Cohort A: up to 22.1 months; Cohort B: up to 21.5 months
Phase 2 (Dose Expansion) Cohorts 4 and 5: Number of Participants With Anti-Drug Antibodies to Alcestobart
Immunogenic responses to alcestobart included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
Time frame: Maximum time on study: Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months
Phase 1: Number of Participants With Anti-Drug Antibodies to Tislelizumab
Immunogenic responses to tislelizumab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
Time frame: Maximum time on study: up to 57.5 months
Phase 2 (Safety Lead-In): Number of Participants With Anti-Drug Antibodies to Tislelizumab
Immunogenic responses to alcestobart included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
Time frame: Maximum time on study: Cohort A: up to 22.1 months; Cohort B: up to 21.5 months
Phase 2 (Dose Expansion): Number of Participants With Anti-Drug Antibodies to Tislelizumab
Immunogenic responses to tislelizumab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
Time frame: Maximum time on study: Cohort 1: up to 31.3 months, Cohort 2: up to 32.0 months, Cohort 4: up to 11.3 months, Cohort 5: up to 15.9 months
Phase 2 (Dose Expansion): Number of Participants With TEAEs and SAEs
An AE was defined as any unfavorable and unintended sign, symptom, or disease associated with the use of study drugs, whether considered related to study drugs or not. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly or was considered a medically significant. TEAE was an AE that has an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of the first new systemic anticancer therapy, whichever occurred first. Severity of AEs was assessed according to NCI-CTCAE v.5.0, which consists of: Grade 1 Mild; Grade 2 Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death due to AE.
Time frame: Up to 30 days after last dose of study drug (maximum treatment duration: Cohort 1: up to 6.9 months, Cohort 2: up to 23.5 months, Cohort 4: up to 9.6 months, Cohort 5: up to 15.4 months)
| Milestone | Phase 1 (Dose Escalation): Surzebiclimab 2 Milligrams (mg) + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + BGB-A425 + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 3 | 5 | 7 | 4 | 7 | 3 | 1 | 1 | 4 | 6 | 6 | 3 | 6 | 6 | 21 | 22 | 20 | 20 |
| Completed | 0 | 0 | 2 | 1 | 5 | 2 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 1 | 4 | 2 | 2 | 3 | 1 | 1 | 1 | 4 | 6 | 6 | 3 | 6 | 6 | 21 | 22 | 20 | 20 |
| Withdrew: Death | 1 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 0 | 2 | 3 | 2 | 0 | 3 | 4 | 15 | 11 | 11 | 8 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 4 | 8 | 2 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 2 | 3 | 2 | 2 | 3 | 7 | 11 |
An Adverse Event (AE) was defined as any unfavorable and unintended sign, symptom, or disease associated with the use of study drugs, whether considered related to study drugs or not. TEAE was an AE that has an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of the first new systemic anticancer therapy, whichever occurred first. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly or was considered a medically significant. Severity of AEs was assessed according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) v.5.0, which consists of: Grade 1 Mild; Grade 2 Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death due to AE.
| Participants | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | 1 | 1 | 3 | 5 | 7 | 4 | 7 | 3 | 1 | 1 |
| Grade 3 or above TEAE | 1 | 0 | 2 | 2 | 3 | 3 | 5 | 1 | 1 | 1 |
| Serious TEAE | 1 | 1 | 3 | 2 | 3 | 2 | 1 | 0 | 1 | 1 |
The MAD was defined as the highest dose administered, where all dose levels were tolerated during dose escalation. The MTD was not reached in Phase 1, therefore the MAD was reported.
| milligram (mg) | Phase 1 (Dose Escalation): Surzebiclimab + Tislelizumab |
|---|---|
| Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of Surzebiclimab in Combination With Tislelizumab | 1600 |
The RP2D or recommended dose for expansion of the combination treatment was determined based upon the MTD or MAD, and also considered the long-term tolerability, PK, efficacy, and any other relevant data as available.
| milligram (mg) | Phase 1 (Dose Escalation): Surzebiclimab + Tislelizumab |
|---|---|
| Phase 1: Recommended Phase 2 Dose (RP2D) of Surzebiclimab in Combination With Tislelizumab | 600 |
An AE was defined as any unfavorable and unintended sign, symptom, or disease associated with the use of study drugs, whether considered related to study drugs or not. TEAE was an AE that has an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of the first new systemic anticancer therapy, whichever occurred first. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly or was considered a medically significant. Severity of AEs was assessed according to NCI-CTCAE v.5.0, which consists of: Grade 1 Mild; Grade 2 Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death due to AE.
| Participants | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab |
|---|---|---|---|---|---|---|
| Any TEAE | 4 | 6 | 6 | 3 | 5 | 6 |
| Grade 3 or above TEAE | 3 | 3 | 4 | 1 | 5 | 4 |
| Serious AE | 3 | 3 | 4 | 1 | 4 | 3 |
The MAD was defined as the highest dose administered, where all dose levels were tolerated during dose escalation. The MTD was not reached in Phase 2, therefore the MAD was reported.
| milligram (mg) | Phase 2 (Safety Lead-In): Alcestobart + Tislelizumab |
|---|---|
| Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Tislelizumab | 1200 |
The MAD was defined as the highest dose administered, where all dose levels were tolerated during dose escalation. The MTD was not reached in Phase 2, therefore the MAD was reported.
| milligram (mg) | Phase 2 (Safety Lead-In): Alcestobart + Surzebiclimab + Tislelizumab |
|---|---|
| Phase 2 (Safety Lead-In): MTD or MAD of Alcestobart in Combination With Surzebiclimab and Tislelizumab | 900 |
The RP2D or recommended dose for expansion of the combination treatment was determined based upon the MTD or MAD, and also considered the long-term tolerability, PK, efficacy, and any other relevant data as available.
| milligram (mg) | Phase 2 (Safety Lead-In): Alcestobart + Surzebiclimab + Tislelizumab |
|---|---|
| Phase 2 (Safety Lead-In): RP2D of Alcestobart in Combination With Surzebiclimab and Tislelizumab | 600 |
ORR was defined as the percentage of participants who had complete response (CR) or partial response (PR). Per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab |
|---|---|---|---|---|
| Phase 2 (Dose Expansion): Overall Response Rate (ORR) | 4.8 (0.1 to 23.8) | 9.1 (1.1 to 29.2) | 0.0 (0.0 to 16.8) | 10.5 (1.3 to 33.1) |
ORR was defined as the percentage of participants who had CR or PR. Per RECIST v.1.1, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Overall Response Rate (ORR) | 0.0 (0.0 to 97.5) | 0.0 (0.0 to 97.5) | 0.0 (0.0 to 70.8) | 0.0 (0.0 to 52.2) | 0.0 (0.0 to 45.9) | 25.0 (0.6 to 80.6) | 14.3 (0.4 to 57.9) | 0.0 (0.0 to 70.8) | 0.0 (0.0 to 97.5) | — |
ORR was defined as the percentage of participants who had CR or PR. Per RECIST v.1.1, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab |
|---|---|---|---|---|---|---|
| Phase 2 (Safety Lead- In): Overall Response Rate (ORR) | 0.0 (0.0 to 60.2) | 33.3 (4.3 to 77.7) | 0.0 (0.0 to 45.9) | 0.0 (0.0 to 70.8) | 0.0 (0.0 to 45.9) | 16.7 (0.4 to 64.1) |
DCR was defined as the percentage of participants with a best overall response (BOR) of CR, PR, or stable disease (SD), per RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study.
| percentage of participants | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Disease Control Rate (DCR) | 0.0 (0.0 to 97.5) | 0.0 (0.0 to 97.5) | 66.7 (9.4 to 99.2) | 40.0 (5.3 to 85.3) | 66.7 (22.3 to 95.7) | 50.0 (6.8 to 93.2) | 57.1 (18.4 to 90.1) | 66.7 (9.4 to 99.2) | 0.0 (0.0 to 97.5) | — |
DCR was defined as the percentage of participants with a BOR of CR, PR, or SD, per RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of participants | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab |
|---|---|---|---|---|---|---|
| Phase 2 (Safety Lead-In): Disease Control Rate (DCR) | 50.0 (6.8 to 93.2) | 83.3 (35.9 to 99.6) | 50.0 (11.8 to 88.2) | 100.0 (29.2 to 100.0) | 50.0 (11.8 to 88.2) | 50.0 (11.8 to 88.2) |
DCR was defined as the percentage of participants with a BOR of CR, PR, or SD, per RECIST v.1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of participants | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab |
|---|---|---|---|---|
| Phase 2 (Dose Expansion): Disease Control Rate (DCR) | 42.9 (21.8 to 66.0) | 45.5 (24.4 to 67.8) | 45.0 (23.1 to 68.5) | 73.7 (48.8 to 90.9) |
DOR was defined as the time from the first determination of an overall response per RECIST v1.1 until the first documentation of progression or death, whichever came first. DOR was estimated using the Kaplan-Meier method. Per RECIST v.1.1., CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
| months | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab |
|---|---|---|---|---|
| Phase 2 (Dose Expansion): Duration of Response (DOR) | 4.0 | 6.9 (5.6 to NA) | — | NA (2.8 to NA) |
Progression free survival was defined as the time from the date of the first dose of study drug(s) to the date of the first documentation of disease progression assessed by investigator or death, whichever occurred first as determined from investigator derived tumor assessments per RECIST 1.1. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study.
| months | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab |
|---|---|---|---|---|
| Phase 2 (Dose Expansion): Progression Free Survival (PFS) | 1.4 (1.4 to 2.6) | 1.7 (1.3 to 4.0) | 1.9 (1.2 to 2.8) | 4.0 (1.4 to 7.2) |
The maximum observed plasma concentration of surzebiclimab was measured in Cycle 1 and Cycle 5.
| micrograms per milliliter (mcg/mL) | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | 0.89 | 5.48 ± 24 | 17.43 ± 38 | 66.50 ± 25 | 145.09 ± 20 | 244.03 ± 25 | 604.10 ± 9 | 19.20 | 534.00 |
| Cycle 5 Day 1 | — | — | 6.96 ± 17 | 26.62 ± 65 | 123.87 ± 14 | 222.86 ± 45 | 470.02 ± 19 | 885.00 | — | — |
| mcg/mL | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab |
|---|---|---|
| Cycle 1 Day 1 | 182.24 ± 17 | 165.62 ± 22 |
| Cycle 5 Day 1 | — | 288.43 ± 31 |
Cmin of surzebiclimab was determined.
| mcg/mL | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | — | — | 1.80 ± 80 | 14.55 ± 49 | 27.84 ± 39 | 62.46 ± 33 | 167.44 ± 27 | — | — |
| Cycle 5 Day 1 | — | — | 0.47 | 6.38 ± 46 | 54.06 ± 8 | 57.43 ± 117 | 173.58 ± 19 | 537.02 | — | — |
| mcg/mL | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab |
|---|---|---|
| Cycle 1 Day 1 | 40.24 ± 26 | 32.27 ± 44 |
| Cycle 5 Day 1 | 116.05 | 87.92 ± 51 |
| hours | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | 1.30 (1.3 to 1.3) | 1.33 (1.1 to 6.1) | 1.15 (1.0 to 1.2) | 1.20 (1.0 to 5.1) | 1.15 (1.0 to 5.2) | 1.10 (1.1 to 6.3) | 1.22 (1.2 to 6.6) | 5.02 | 1.58 |
| Cycle 5 Day 1 | — | — | 2.93 (0.7 to 5.2) | 0.72 (0.7 to 0.8) | 0.57 (0.5 to 0.6) | 5.66 (4.7 to 6.6) | 0.92 (0.6 to 6.7) | 0.62 | — | — |
| hours | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab |
|---|---|---|
| Cycle 1 Day 1 | 4.54 (4.1 to 5.0) | 4.00 (1.0 to 23.6) |
| Cycle 5 Day 1 | — | 2.78 (0.5 to 22.3) |
| hours | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Half-Life (t1/2) of Surzebiclimab | — | — | 122.20 (117.9 to 126.5) | 203.43 (139.2 to 246.1) | 276.06 (174.4 to 628.5) | 344.59 (338.2 to 674.2) | 356.26 (327.9 to 512.2) | 643.02 | — | 99.20 |
| hours | Phase 2 (Dose Expansion): Cohort 1: HNSCC: BGB A425 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: BGB A425 600 mg + Tislelizumab |
|---|---|---|
| Phase 2 (Dose Expansion): T1/2 of Surzebiclimab | 325.65 (224.5 to 523.7) | 274.83 (216.5 to 462.6) |
| hours*mcg/mL | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | — | 727.11 ± 31 | 2734.25 ± 44 | 12911.99 ± 34 | 25213.19 ± 30 | 50478.81 ± 25 | 153224.06 | — | 70304.42 |
| Cycle 5 Day 1 | — | — | 999.31 ± 36 | 5518.62 ± 29 | 38776.66 ± 1 | 34857.77 | 138368.71 ± 20 | 303366.23 | — | — |
| hours*mcg/mL | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab |
|---|---|---|
| Cycle 1 Day 1 | 37538.32 ± 15 | 31104.68 ± 26 |
| Cycle 5 Day 1 | 90437.84 | 66659.54 ± 34 |
| Liters per hour (L/h) | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Clearance (CL/F) of Surzebiclimab | — | — | 0.03 ± 28 | 0.02 ± 50 | 0.01 ± 57 | 0.01 ± 42 | 0.01 ± 11 | 0.00 | — | 0.02 |
| Liters per hour (L/h) | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab |
|---|---|---|
| Phase 2 (Dose Expansion): CL/F of Surzebiclimab | 0.01 ± 21 | 0.01 ± 38 |
| Liters (L) | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Volume of Distribution (Vz/F) of Surzebiclimab | — | — | 4.43 ± 33 | 5.04 ± 37 | 4.48 ± 22 | 5.55 ± 30 | 5.56 ± 34 | 4.38 | — | 3.15 |
Vz/F of surzebiclimab was determined.
| Liters (L) | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab |
|---|---|---|
| Phase 2 (Dose Expansion): Vz/F of Surzebiclimab | 4.98 ± 33 | 5.69 ± 16 |
| mcg/mL | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab |
|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 61.21 ± 51 | 112.96 ± 24 | 242.51 ± 19 | 61.39 ± 32 | 115.74 ± 25 | 149.57 ± 28 |
| Cycle 5 Day 1 | 57.60 | 177.18 ± 15 | 294.49 ± 17 | 86.40 | 139.24 ± 9 | 245.81 ± 45 |
Cmin of alcestobart was determined.
| mcg/mL | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab |
|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2.01 ± 300 | 24.07 ± 40 | 35.38 ± 27 | 9.32 ± 62 | 12.81 ± 43 | 26.44 ± 52 |
| Cycle 5 Day 1 | — | 40.66 ± 30 | 77.79 ± 18 | 15.95 | 32.55 ± 14 | 67.12 |
| hours | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab |
|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 1.48 (1.2 to 1.8) | 2.84 (1.4 to 5.4) | 1.54 (1.2 to 6.0) | 1.42 (1.3 to 4.3) | 1.29 (1.2 to 6.1) | 1.28 (1.0 to 1.8) |
| Cycle 5 Day 1 | 0.83 | 4.57 (0.9 to 22.0) | 11.97 (0.6 to 23.4) | 0.67 | 4.18 (4.1 to 4.3) | 0.83 (0.7 to 1.0) |
| hours | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab |
|---|---|---|---|---|---|---|
| Phase 2 (Safety Lead-In): t1/2 of Alcestobart | 143.35 (56.5 to 214.8) | 248.79 (195.6 to 380.4) | 227.76 (188.8 to 284.1) | 230.84 (167.5 to 234.5) | 200.74 (152.4 to 255.5) | 262.83 (152.7 to 333.7) |
| hours*mcg/mL | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab |
|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 8620.04 ± 34 | 21120.06 ± 15 | 41874.14 ± 26 | 10947.98 ± 35 | 18655.37 ± 25 | 30906.45 ± 25 |
| Cycle 5 Day 1 | — | 41698.19 ± 20 | 67245.59 ± 20 | 16445.08 | 32044.03 ± 12 | 49948.77 ± 54 |
| L/h | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + BGB-A425 + Tislelizumab |
|---|---|---|---|---|---|---|
| Phase 2 (Safety Lead-In): CL/F of Alcestobart | 0.03 ± 37 | 0.02 ± 31 | 0.02 ± 26 | 0.02 ± 40 | 0.03 ± 26 | 0.02 ± 36 |
| Liters | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab |
|---|---|---|---|---|---|---|
| Phase 2 (Safety Lead-In): Vz/F of Alcestobart | 5.48 ± 77 | 7.83 ± 10 | 7.29 ± 31 | 6.40 ± 29 | 7.59 ± 26 | 7.81 ± 20 |
Serum concentrations of tislelizumab were measured using an enzyme-linked immunosorbent assay (ELISA).
| mcg/mL | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 8: Pre-dose | — | — | — | — | 0.68 | — | 2.70 | — |
| Cycle 1 Day 8: End of Infusion | 40.50 | 51.10 | 57.91 ± 24 | 54.87 ± 46 | 64.19 ± 26 | 66.23 ± 25 | 67.66 ± 20 | 64.05 ± 15 |
| Cycle 2 Day 1: Pre-dose | 12.20 | 14.00 | 28.29 ± 108 | 17.31 ± 24 | 17.75 ± 44 | 15.93 ± 37 | 16.68 ± 26 | 18.71 ± 38 |
| Cycle 3 Day 1: Pre-dose | — | — | 27.60 | 49.64 ± 201 | 34.83 ± 78 | 26.40 ± 79 | 28.20 | 35.90 |
| Cycle 5 Day 1: Pre-dose | — | — | 34.50 ± 71 | 49.31 ± 18 | 64.82 ± 4 | 38.24 ± 81 | 44.59 ± 22 | 55.20 |
| Cycle 5 Day 1: End of Infusion | — | — | 82.60 | 110.68 ± 26 | 122.85 ± 7 | 116.81 ± 53 | 100.66 ± 25 | 92.90 |
| Cycle 6 Day 1: Pre-dose | — | — | 46.58 ± 44 | 51.39 ± 35 | 69.54 ± 2 | 33.54 ± 87 | 41.83 ± 31 | 58.10 |
| Cycle 9 Day 1: Pre-dose | — | — | 57.95 ± 6 | — | 70.90 | 24.10 | 45.14 ± 3 | 72.20 |
| Cycle 13 Day 1: Pre-dose | — | — | 90.00 | — | 51.90 | — | 46.28 ± 4 | — |
| Cycle 17 Day 1: Pre-dose | — | — | 87.90 | — | — | — | 45.79 ± 3 | — |
| Cycle 25 Day 1: Pre-dose | — | — | 103.00 | — | — | — | 43.04 ± 10 | — |
Serum concentrations of tislelizumab were measured using an enzyme-linked immunosorbent assay (ELISA).
| mcg/mL | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab |
|---|---|---|---|---|
| Cycle 1 Day 1: Pre-dose | 9.09 ± 137 | 10.61 ± 593 | 26.45 ± 125 | 13.57 ± 187 |
| Cycle 1 Day 1: EOI | 62.51 ± 30 | 77.36 ± 32 | 95.63 ± 69 | 60.27 ± 30 |
| Cycle 2 Day 1: Pre-dose | 20.35 ± 39 | 23.46 ± 84 | 25.92 ± 103 | 19.76 ± 73 |
| Cycle 5 Day 1: Pre-dose | 34.47 ± 61 | 39.51 ± 39 | 35.54 ± 83 | 32.96 ± 43 |
| Cycle 5 Day 1: EOI | 84.82 ± 20 | 102.93 ± 18 | 106.79 ± 76 | 96.71 ± 75 |
| Cycle 6 Day 1: Pre-dose | 28.12 ± 37 | 41.92 ± 47 | 33.02 ± 178 | 32.56 ± 48 |
| Cycle 9 Day 1: Pre-dose | 29.70 | 45.83 ± 28 | 71.20 | 39.05 ± 33 |
| Cycle 13 Day 1: Pre-dose | — | 49.57 ± 47 | 64.20 | 34.88 ± 44 |
| Cycle 17 Day 1: Pre-dose | — | 37.68 ± 60 | — | 38.54 ± 31 |
| Cycle 25 Day 1: Pre-dose | — | 63.70 | — | — |
Immunogenic responses to surzebiclimab included: treatment emergent, treatment-induced and treatment boosted anti-drug antibodies (ADA) and neutralizing antibody (NAb) positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the Baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive Nab at any time including baseline and/or after drug administration.
| Participants | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab |
|---|---|---|---|---|---|---|---|---|
| Treatment-Emergent ADAs | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Treatment-Induced ADAs | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Treatment-Boosted ADAs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NAb Positive | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Immunogenic responses to surzebiclimab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
| Participants | Phase 2 (Safety Lead-In): Cohort B: LBL-007 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab |
|---|---|---|---|
| Treatment-Emergent ADAs | 0 | 1 | 0 |
| Treatment-Induced ADAs | 0 | 1 | 0 |
| Treatment-Boosted ADAs | 0 | 0 | 0 |
| NAb Positive ADAs | 0 | 0 | 0 |
Immunogenic responses to surzebiclimab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
| Participants | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab |
|---|---|---|---|---|
| Treatment-Emergent ADAs | 2 | 4 | 0 | 1 |
| Treatment-Induced ADAs | 2 | 4 | 0 | 1 |
| Treatment-Boosted ADAs | 0 | 0 | 0 | 0 |
| NAb Positive ADAs | 0 | 1 | 0 | 0 |
Immunogenic responses to alcestobart included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
| Participants | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab |
|---|---|---|---|---|---|---|
| Treatment-Emergent ADAs | 2 | 0 | 0 | 0 | 1 | 0 |
| Treatment-Induced ADAs | 2 | 0 | 0 | 0 | 1 | 0 |
| Treatment-Boosted ADAs | 0 | 0 | 0 | 0 | 0 | 0 |
| NAb Positive ADAs | 0 | 0 | 1 | 0 | 1 | 0 |
Immunogenic responses to alcestobart included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
| Participants | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab |
|---|---|---|
| Treatment-Emergent ADAs | 0 | 0 |
| Treatment-Induced ADAs | 0 | 0 |
| Treatment-Boosted ADAs | 0 | 0 |
| NAb-Positive ADAs | 0 | 1 |
Immunogenic responses to tislelizumab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
| Participants | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab |
|---|---|---|---|---|---|---|---|---|
| Treatment-Emergent ADAs | — | 0 | 1 | 1 | 0 | 1 | 2 | 0 |
| Treatment-Induced ADAs | — | 0 | 1 | 1 | 0 | 1 | 2 | 0 |
| Treatment-Boosted ADAs | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NAb Positive ADAs | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Immunogenic responses to alcestobart included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
| Participants | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab |
|---|---|---|---|---|---|---|
| Treatment-Emergent ADAs | 3 | 1 | 0 | 0 | 3 | 1 |
| Treatment-Induced ADAs | 3 | 1 | 0 | 0 | 2 | 1 |
| Treatment-Boosted ADAs | 0 | 0 | 0 | 0 | 1 | 0 |
| NAb Positive ADAs | 1 | 0 | 0 | 0 | 1 | 0 |
Immunogenic responses to tislelizumab included: treatment-emergent, treatment-induced and treatment-boosted ADA and NAb positive assessments. Treatment-emergent ADA was defined as the sum of treatment-boosted ADA and treatment-induced ADA participants. Treatment-induced ADA was defined as ADA-evaluable participants that were ADA-negative at baseline and ADA-positive after drug administration during the treatment or follow-up observation period. Treatment-boosted ADA was defined as the baseline-positive ADA-evaluable participants with significant increases (4-fold or higher) in ADA titer after drug administration during the treatment or follow-up observation period. NAb positive was defined as ADA-evaluable participants with positive NAb at any time including baseline and/or after drug administration.
| Participants | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab |
|---|---|---|---|---|
| Treatment-Emergent ADAs | 7 | 10 | 5 | 4 |
| Treatment-Induced ADAs | 7 | 9 | 4 | 4 |
| Treatment-Boosted ADAs | 0 | 1 | 1 | 0 |
| NAb Positive ADAs | 0 | 0 | 0 | 0 |
An AE was defined as any unfavorable and unintended sign, symptom, or disease associated with the use of study drugs, whether considered related to study drugs or not. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly or was considered a medically significant. TEAE was an AE that has an onset date or a worsening in severity from baseline on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of the first new systemic anticancer therapy, whichever occurred first. Severity of AEs was assessed according to NCI-CTCAE v.5.0, which consists of: Grade 1 Mild; Grade 2 Moderate; Grade 3: Severe; Grade 4: Life-threatening; Grade 5: Death due to AE.
| Participants | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab |
|---|---|---|---|---|
| Any TEAE | 20 | 21 | 20 | 20 |
| Grade 3 or above TEAE | 11 | 11 | 9 | 9 |
| Serious TEAE | 9 | 8 | 6 | 9 |
Collected over All cause-mortality data was collected from randomization through end of study (up to 6 years 3 months). SAEs & nonserious AEs data: up to 30 days after last dose of study drugs (Maximum treatment duration: up to 32.7 months [Phase 1]; Cohort A: up to 19.6 months; Cohort B: up to 21.5 months [Phase 2 Safety Lead-In] and Cohort 1: up to 6.9 months, Cohort 2: up to 23.5 months, Cohort 4: up to 9.6 months, Cohort 5: up to 15.4 months [Phase 2 Dose Expansion]). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | 0/3 (0%) | 3/3 (100%) | 3/3 (100%) |
| Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | 1/5 (20%) | 2/5 (40%) | 4/5 (80%) |
| Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | 1/7 (14.3%) | 3/7 (42.9%) | 7/7 (100%) |
| Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | 1/7 (14.3%) | 1/7 (14.3%) | 7/7 (100%) |
| Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | 1/3 (33.3%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1 (Dose Escalation): Surzebiclimab 60 mg | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Phase 1 (Dose Escalation): Surzebiclimab 1600 mg | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | 2/4 (50%) | 3/4 (75%) | 4/4 (100%) |
| Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | 3/6 (50%) | 3/6 (50%) | 6/6 (100%) |
| Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | 2/6 (33.3%) | 4/6 (66.7%) | 6/6 (100%) |
| Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | 3/6 (50%) | 4/6 (66.7%) | 4/6 (66.7%) |
| Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab | 4/6 (66.7%) | 3/6 (50%) | 6/6 (100%) |
| Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | 15/21 (71.4%) | 9/21 (42.9%) | 20/21 (95.2%) |
| Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | 11/22 (50%) | 8/22 (36.4%) | 20/22 (90.9%) |
| Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | 11/20 (55%) | 6/20 (30%) | 20/20 (100%) |
| Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | 8/20 (40%) | 9/20 (45%) | 20/20 (100%) |
| Event | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/1 | 0/1 | 0/3 | 0/5 | 0/7 | 0/4 | 0/7 | 0/3 | 1/1 | 0/1 | 0/4 | 0/6 | 0/6 | 0/3 | 1/6 | 0/6 | 0/21 | 0/22 | 0/20 | 0/20 |
| Abdominal pain lowerGastrointestinal disorders | 0/1 | 0/1 | 0/3 | 0/5 | 0/7 | 0/4 | 0/7 | 0/3 | 1/1 | 0/1 | 0/4 | 0/6 | 0/6 | 0/3 | 0/6 | 0/6 | 0/21 | 0/22 | 0/20 | 0/20 |
| Gastric perforationGastrointestinal disorders | 0/1 | 0/1 | 0/3 | 0/5 | 0/7 | 0/4 | 0/7 | 0/3 | 0/1 | 1/1 | 0/4 | 0/6 | 0/6 | 0/3 | 0/6 | 0/6 | 0/21 | 0/22 | 0/20 | 0/20 |
| Small intestinal obstructionGastrointestinal disorders | 1/1 | 0/1 | 0/3 | 0/5 | 0/7 | 0/4 | 0/7 | 0/3 | 0/1 | 0/1 | 0/4 | 0/6 | 0/6 | 0/3 | 0/6 | 0/6 | 0/21 | 0/22 | 0/20 | 0/20 |
| Bone painMusculoskeletal and connective tissue disorders | 0/1 | 1/1 | 0/3 | 0/5 | 0/7 | 0/4 | 0/7 | 0/3 | 0/1 | 0/1 | 0/4 | 0/6 | 0/6 | 0/3 | 0/6 | 0/6 | 0/21 | 0/22 | 0/20 | 0/20 |
| Acute kidney injuryRenal and urinary disorders | 0/1 | 0/1 | 0/3 | 0/5 | 0/7 | 0/4 | 0/7 | 0/3 | 0/1 | 1/1 | 0/4 | 0/6 | 0/6 | 0/3 | 0/6 | 0/6 | 0/21 | 0/22 | 0/20 | 0/20 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/1 | 1/1 | 0/3 | 0/5 | 0/7 | 0/4 | 0/7 | 0/3 | 0/1 | 0/1 | 0/4 | 0/6 | 0/6 | 0/3 | 0/6 | 0/6 | 1/21 | 3/22 | 1/20 | 1/20 |
| HypothyroidismEndocrine disorders | 0/1 | 0/1 | 0/3 | 0/5 | 0/7 | 0/4 | 0/7 | 0/3 | 0/1 | 0/1 | 0/4 | 0/6 | 0/6 | 1/3 | 0/6 | 0/6 | 0/21 | 0/22 | 0/20 | 0/20 |
| Abdominal painGastrointestinal disorders | 0/1 | 0/1 | 1/3 | 1/5 | 0/7 | 0/4 | 0/7 | 0/3 | 0/1 | 0/1 | 0/4 | 0/6 | 0/6 | 0/3 | 0/6 | 0/6 | 0/21 | 0/22 | 0/20 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 0/1 | 1/3 | 0/5 | 0/7 | 0/4 | 0/7 | 0/3 | 0/1 | 0/1 | 0/4 | 0/6 | 0/6 | 0/3 | 0/6 | 0/6 | 0/21 | 0/22 | 0/20 | 0/20 |
| Event | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AscitesGastrointestinal disorders | 1/1 | 0/1 | 0/3 | 0/5 | 0/7 | 0/4 | 0/7 | 0/3 | 0/1 | 0/1 | 0/4 | 0/6 | 0/6 | 0/3 | 0/6 | 0/6 | 0/21 | 0/22 | 0/20 | 0/20 |
| ConstipationGastrointestinal disorders | 1/1 | 0/1 | 0/3 | 1/5 | 0/7 | 1/4 | 1/7 | 0/3 | 1/1 | 0/1 | 1/4 | 0/6 | 1/6 | 0/3 | 1/6 | 0/6 | 1/21 | 6/22 | 0/20 | 1/20 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 1/1 | 2/3 | 0/5 | 0/7 | 0/4 | 2/7 | 0/3 | 0/1 | 1/1 | 2/4 | 3/6 | 1/6 | 0/3 | 0/6 | 0/6 | 6/21 | 3/22 | 1/20 | 5/20 |
| NauseaGastrointestinal disorders | 1/1 | 1/1 | 2/3 | 0/5 | 1/7 | 2/4 | 2/7 | 0/3 | 1/1 | 0/1 | 1/4 | 2/6 | 1/6 | 2/3 | 2/6 | 3/6 | 5/21 | 5/22 | 3/20 | 5/20 |
| FatigueGeneral disorders and administration site conditions | 0/1 | 1/1 | 1/3 | 1/5 | 0/7 | 2/4 | 3/7 | 0/3 | 0/1 | 0/1 | 1/4 | 2/6 | 2/6 | 1/3 | 2/6 | 1/6 | 12/21 | 6/22 | 4/20 | 3/20 |
| Oedema peripheralGeneral disorders and administration site conditions | 1/1 | 0/1 | 1/3 | 0/5 | 1/7 | 2/4 | 1/7 | 0/3 | 0/1 | 1/1 | 0/4 | 1/6 | 0/6 | 0/3 | 0/6 | 0/6 | 2/21 | 2/22 | 0/20 | 1/20 |
| Alanine aminotransferase increasedInvestigations | 0/1 | 0/1 | 1/3 | 0/5 | 0/7 | 0/4 | 2/7 | 0/3 | 1/1 | 0/1 | 0/4 | 0/6 | 0/6 | 0/3 | 1/6 | 1/6 | 2/21 | 3/22 | 0/20 | 2/20 |
| Aspartate aminotransferase increasedInvestigations | 0/1 | 0/1 | 0/3 | 0/5 | 0/7 | 0/4 | 2/7 | 0/3 | 1/1 | 0/1 | 0/4 | 0/6 | 0/6 | 0/3 | 1/6 | 1/6 | 2/21 | 3/22 | 1/20 | 2/20 |
| Blood bilirubin increasedInvestigations | 0/1 | 0/1 | 0/3 | 0/5 | 0/7 | 0/4 | 1/7 | 0/3 | 1/1 | 0/1 | 1/4 | 0/6 | 0/6 | 0/3 | 0/6 | 0/6 | 0/21 | 0/22 | 1/20 | 0/20 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/1 | 0/1 | 0/3 | 0/5 | 0/7 | 0/4 | 0/7 | 0/3 | 0/1 | 0/1 | 0/4 | 0/6 | 2/6 | 0/3 | 0/6 | 0/6 | 0/21 | 0/22 | 0/20 | 0/20 |
Analysis was performed on Safety Analysis Set which included all participants who received at least 1 dose of study drug(s).
| Age, Continuous(years) | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 66.0 | 66.0 | 53.3 ± 20.84 | 60.6 ± 7.80 | 62.9 ± 8.57 | 58.8 ± 4.19 | 58.7 ± 9.79 | 45.3 ± 15.95 | 47.0 | 56.0 | 61.0 ± 8.16 | 65.3 ± 7.99 | 63.0 ± 9.32 | 61.3 ± 16.07 | 61.5 ± 13.50 | 65.5 ± 6.66 | 60.9 ± 7.91 | 64.5 ± 7.52 | 64.2 ± 9.57 | 65.4 ± 9.18 | 62.4 ± 9.50 |
| Sex: Female, Male(Participants) | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 2 | 2 | 6 | 4 | 3 | 1 | 1 | 1 | 3 | 3 | 2 | 2 | 2 | 3 | 2 | 8 | 7 | 4 | 57 |
| Male | 0 | 1 | 1 | 3 | 1 | 0 | 4 | 2 | 0 | 0 | 1 | 3 | 4 | 1 | 4 | 3 | 19 | 14 | 13 | 16 | 90 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 5 |
| Not Hispanic or Latino | 1 | 1 | 3 | 4 | 7 | 4 | 7 | 3 | 1 | 1 | 4 | 5 | 5 | 3 | 6 | 5 | 21 | 22 | 17 | 17 | 137 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 5 |
| Race/Ethnicity, Customized(Participants) | Phase 1 (Dose Escalation): Surzebiclimab 2 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 6 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 20 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 200 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 400 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 800 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg + Tislelizumab | Phase 1 (Dose Escalation): Surzebiclimab 60 mg | Phase 1 (Dose Escalation): Surzebiclimab 1600 mg | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 300 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 600 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort A: Alcestobart 1200 mg + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 300 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 600 mg + Surzebiclimab + Tislelizumab | Phase 2 (Safety Lead-In): Cohort B: Alcestobart 900 mg + Surzebiclimab + Tislelizumab | Phase 2 (Dose Expansion): Cohort 1: HNSCC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 2: NSCLC: Surzebiclimab 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 4: HNSCC Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Phase 2 (Dose Expansion): Cohort 5: NSCLC: Surzebiclimab 600 mg + Alcestobart 600 mg + Tislelizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 6 | 14 | 2 | 2 | 27 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 0 | 7 |
| White | 1 | 1 | 3 | 5 | 6 | 3 | 7 | 2 | 1 | 0 | 3 | 5 | 6 | 2 | 5 | 5 | 14 | 7 | 9 | 13 | 98 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 5 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from Nov 2018 to primary completion in Feb 2025, 74 months.
Results were first posted in Apr 2026, 1 year 1 month after primary completion.
Of 93 industry-sponsored phase 1/2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's 74 months is above that.
Counting every sponsor, half of 138 studies reached it within 61 months; a quarter within 47 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tislelizumab · Alcestobart
Squamous Cell Carcinoma of Head and Neck →